Lebrikizumab

Eli Lilly announces FDA approval of Ebglyss for adults and children over 12 with moderate-to-severe eczema, available in weeks. Approval follows three studies on over 1,000 patients unresponsive to other treatments. The drug was previously denied approval due to inspection issues at a contract manufacturer.

FDA approves Ebglyss, a targeted interleukin-13 inhibitor for moderate-to-severe atopic dermatitis, offering clear skin in 38% of patients at 16 weeks and itch relief in 43% at 16 weeks, with maintenance dosing.

FDA approves Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for moderate-to-severe atopic dermatitis in adults and children 12+ years old, not well controlled by topical therapies. Ebglyss, dosed monthly after initial treatment, offers significant skin clearance and itch relief, with common side effects including eye and eyelid inflammation, injection site reactions, and shingles.

Ebglyss, a new first-line biologic treatment for moderate-to-severe atopic dermatitis, offers significant skin clearance within four weeks and itch relief in two weeks. It provides long-lasting efficacy through monthly maintenance doses, approved by the FDA for adults and children 12 years and older who weigh at least 88 pounds (40 kg) and have inadequate response to topical therapies.

La-Z-Boy (LZB) is highlighted as a strong buy with a Zacks Rank #1, showcasing resilience and strategic growth despite market challenges. Winnebago Industries (WGO) is a strong sell due to disappointing earnings and lower estimates. Eli Lilly (LLY) shows promise with its drug tirzepatide for sleep apnea and obesity, alongside a robust pipeline. Novo Nordisk (NVO) and Biogen (BIIB) are also noted for their contributions to the pharmaceutical sector.

Eli Lilly's tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, shows promise in treating sleep apnea, with recent studies indicating significant reductions in sleep apnea events. Lilly seeks FDA approval for this expanded use, potentially boosting sales. The company's strong pipeline, including Alzheimer's drug donanemab, and robust financial performance, driven by high demand for its drugs, position it well for future growth.